Project Grant R21CA299786
Award Date
4/15/25
Completion Date
3/31/27
Dollars Obligated
$235K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $641,336 over a 5-year period beginning September 1, 2024 to support research on targeting the GARP-TGFβ axis to improve immunotherapy for non-small cell lung cancer (NSCLC). The primary awardee, The Ohio State University, will conduct preclinical studies evaluating an anti-GARP antibody (PIIO-1) to enhance CD8+ T cell function and overcome resistance to immune checkpoint...
The National Cancer Institute awarded a $183,398 Project Grant to The Ohio State University under the Cancer Research Manpower (CFDA 93.398) program. The grant, titled "Targeting Mitochondrial Oxygen Demand to Overcome Hypoxic Immune Privilege of NSCLC Tumors," will investigate the role of tumor hypoxia in modulating immune privilege in non-small cell lung cancer (NSCLC) models. The project aims to elucidate the tumor microenvironment-specific mechanisms of hypoxic immune privilege...
The National Cancer Institute (NCI) awarded a 5-year, $231,870 Project Grant under the CFDA 93.398 Cancer Research Manpower program to The Washington University in St. Louis. The goal of this research project is to investigate how lung fibrosis impairs tumor immunity and limits the efficacy of immune checkpoint inhibitors for non-small cell lung cancer (NSCLC). The research will utilize a genetically engineered mouse model of lung adenocarcinoma to assess how targeting fibrosis via TGF-beta...
The Project Grant award R21CA289134, funded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research to advance immunotherapy approaches for non-small cell lung cancer (NSCLC). The award, totaling $450,429, aims to investigate how the MUC1-C protein contributes to immune evasion in EGFR-mutant NSCLC, and to evaluate whether targeting MUC1-C with antibody-drug conjugates can reverse immune suppression and improve responses to immune...
The National Cancer Institute awarded a 5-year, $483,706 Project Grant (CFDA 93.396 Cancer Biology Research) to The Trustees of the University of Pennsylvania to study the regulation of immune cells called tumor-associated macrophages (TAMs) in the tumor microenvironment. The research aims to elucidate how changes in the composition and activity of the mitochondrial enzyme complex IV in TAMs, driven by the expression of NDUFA4L3 and miR-147, modulate TAM function and anti-tumor immunity. The...
The federal Project Grant award of $433,157 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Endeavor Health Clinical Operations, Northshore University Healthsystem Research Institute Division, supports research investigating the role of lipid-rich macrophages in the tumor microenvironment of prostate cancer. The study aims to determine whether altering the activity of certain enzymes and proteins involved in lipid metabolism and inflammatory signaling in these...
The National Cancer Institute (NCI) awarded The Ohio State University a $281,370 Project Grant under the Cancer Research Manpower (CFDA 93.398) program. The award, titled "Biomarker-Driven Strategies to Overcome Immunotherapy Resistance in STK11-Deficient NSCLC", aims to characterize the interaction between tumor differentiation phenotypes, corresponding immune tumor microenvironment phenotypes, and clinical response to immune checkpoint blockade in lung cancers with STK11...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine will support a comprehensive research program aimed at understanding and disrupting the adeno-to-squamous transition (AST) observed in non-small cell lung cancer (NSCLC) patients treated with KRAS inhibitor drugs. The $703,410 award, effective January 16, 2025 through December 31, 2029, will fund investigations to identify chromatin regulators that drive...
This federal Project Grant award of $230,010 from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to investigate the underlying mechanisms driving the aggressive metastasis of small cell lung cancer (SCLC). The project utilizes innovative methods including human pluripotent stem cell-derived pulmonary neuroendocrine cells, clinical samples, patient-derived xenografts, and advanced technologies such as single-cell sequencing and...
This $107,948 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) supports research conducted by Case Western Reserve University (CWRU) to understand the immune response against the EGFR L858R mutation in lung cancer. The project aims to fully define the immunogenic properties of the L858R neoantigen and the ability of EGFR L858R-specific T cells to suppress tumor growth. The research employs cutting-edge genetic and computational...